MGF (Mechano Growth Factor) for Muscle Repair & Recovery

Candidate profile

Individuals with acute or recurring muscle damage who need to accelerate the repair-regeneration cycle. MGF (Mechano Growth Factor) is specifically relevant when the limiting factor in recovery is satellite cell activation — the initial step in muscle repair where dormant stem cells are recruited to the damage site.

Typical candidate profiles include:

• Athletes in intensive training phases where training frequency exceeds natural recovery capacity (e.g., twice-daily training, high-volume hypertrophy blocks)
• Individuals recovering from muscle strains (grade I-II) where accelerated repair enables earlier return to activity
• Older adults (40+) with demonstrably slowed recovery between training sessions, reflecting age-related decline in satellite cell responsiveness
• Bodybuilders during high-volume training phases where muscle damage accumulates faster than repair
• Individuals returning to training after prolonged detraining (months of inactivity) who experience severe DOMS and extended recovery times

Not appropriate for complete muscle tears (grade III) requiring surgical repair. MGF supports regeneration of damaged fibers, not structural reconstruction. Also not a substitute for adequate rest, nutrition, and programming — MGF amplifies the repair signal but cannot compensate for chronic overtraining or nutritional deficit.

Important biological context: MGF is a splice variant of IGF-1, not a separate gene product. When muscle tissue is mechanically loaded or damaged, the IGF-1 gene is alternatively spliced to produce MGF (also called IGF-1Ec in humans). This mechano-sensitive variant is expressed locally at the damage site within hours of exercise, where it activates satellite cells before being replaced by systemic IGF-1Ea expression that drives the later proliferation and differentiation phases. Exogenous MGF administration amplifies this natural post-exercise signal.

Approach

Intramuscular MGF injection into damaged or trained muscle to amplify the initial satellite cell activation signal. The rationale is timing-specific: MGF acts in the first 24-48 hours after muscle damage to wake up dormant satellite cells and initiate their proliferation. After this window, the local MGF signal is naturally replaced by IGF-1Ea (the systemic isoform) which drives satellite cell differentiation and fusion with damaged fibers.

The mechanism is distinct from IGF-1 LR3. Where IGF-1 LR3 drives proliferation and protein synthesis (later repair phases), MGF operates upstream — it activates quiescent satellite cells and initiates their entry into the cell cycle. In the natural repair sequence:

1. Mechanical damage occurs
2. MGF is expressed locally (hours 0-24)
3. Satellite cells activate and begin proliferating
4. MGF expression declines, replaced by IGF-1Ea
5. IGF-1Ea drives satellite cell differentiation and fiber repair

Exogenous MGF amplifies step 2, ensuring a larger pool of activated satellite cells enters the proliferative phase. This translates to faster and more complete repair.

The challenge with native MGF is its extremely short half-life — approximately 5-7 minutes in circulation. This is actually physiologically appropriate (the signal is meant to be local and transient), but it means injection must be directly into the target muscle, and timing relative to exercise is critical.

Protocol design

Peptide: MGF (IGF-1Ec C-terminal peptide)

Route: Intramuscular injection into the trained/damaged muscle group

Dose: 100-200 mcg per muscle group, bilateral injection

Timing: Immediately post-exercise (within 30 minutes of completing the training session for the target muscle)

Frequency: Training days only, into the muscles trained that session

Standard protocol:

• Inject 100-200 mcg into each side of the trained bilateral muscle group immediately after training
• Example: after a leg session, 150 mcg into each quadricep (300 mcg total)
• For unilateral muscles (e.g., each head of the triceps), distribute the dose across the muscle belly
• Inject into the muscle belly, not the tendon insertion or musculotendinous junction

MGF + IGF-1 LR3 sequential protocol (advanced):

• Inject MGF immediately post-workout into the trained muscle (satellite cell activation)
• Wait 15-30 minutes
• Inject IGF-1 LR3 (20-40 mcg) into the same muscle (satellite cell proliferation and protein synthesis)
• This sequence mirrors the natural MGF-then-IGF-1 cascade in an amplified form

PEG-MGF alternative:

• PEG-MGF (pegylated MGF) has a dramatically extended half-life (hours vs. minutes) due to polyethylene glycol conjugation
• Dose: 200-400 mcg, administered subcutaneously or intramuscularly
• Frequency: 2-3 times per week (vs. daily for native MGF)
• Trade-off: PEG-MGF provides systemic satellite cell activation rather than the local, transient signal of native MGF. The extended half-life loses the temporal specificity of the natural MGF pulse but gains convenience and systemic coverage

Cycle duration: 4-6 weeks. MGF cycles are typically shorter than other peptide cycles because the goal is recovery enhancement during a specific high-volume training block, not chronic supplementation.

Reconstitution: Reconstitute with bacteriostatic water or 0.6% acetic acid. Typical reconstitution: 1 mL to a 2 mg vial = 2000 mcg/mL. A 200 mcg dose = 0.1 mL.

Storage: Refrigerate at 2-8 degrees C. MGF is relatively unstable — use within 2-3 weeks of reconstitution.

Expected timeline

Days 1-3: Enhanced post-exercise pump and localized muscle fullness in injected muscles. These effects reflect local satellite cell activation and the inflammatory response that accompanies repair initiation. DOMS may be slightly reduced in intensity but not eliminated — the inflammatory signaling that causes soreness is part of the repair cascade, not just a pain symptom.

Week 1: Reduced recovery time between sessions becomes noticeable. Muscles that previously required 72 hours to recover from a high-volume session may recover in 48-60 hours. This is the first functional indicator that satellite cell activation is accelerating the repair timeline.

Weeks 2-3: Training volume capacity increases. The ability to tolerate higher session frequency or volume for target muscle groups improves. Strength that was previously lost in the days following a hard session returns more quickly.

Weeks 4-6: Cumulative effect on muscle quality and repair capacity. Hypertrophy gains during this period may exceed baseline training response, as the enhanced satellite cell activation increases the myonuclear domain — each fiber accumulates more nuclei, expanding its long-term growth capacity. This is the mechanistic basis for MGF's contribution to hypertrophy beyond simple recovery.

Post-cycle: The myonuclei added during the MGF-enhanced repair cycles are permanent (muscle memory concept). The enhanced recovery rate returns to baseline after discontinuation, but the structural improvements (additional myonuclei, repaired damage) persist.

Complementary peptides

• IGF-1 LR3: The most mechanistically logical complement. MGF activates satellite cells; IGF-1 LR3 drives their proliferation and differentiation. The sequential injection protocol (MGF first, IGF-1 LR3 15-30 minutes later) recapitulates the natural growth factor cascade.
• BPC-157: If muscle damage extends to connective tissue (musculotendinous junction injuries, muscle strains), BPC-157 (250 mcg SC near the injury) supports the connective tissue component that MGF does not address. MGF targets myofiber repair; BPC-157 targets the extracellular matrix and vascular components.
• TB-500: Systemic tissue repair peptide that complements MGF's localized action. TB-500 promotes cell migration and neovascularization systemically, supporting repair across all damaged tissues. Particularly useful when training volume damages multiple tissue types simultaneously.
• CJC-1295/Ipamorelin (bedtime): Nocturnal GH elevation supports overall recovery and endogenous IGF-1 production. This systemic support complements MGF's localized, acute action.

Evidence assessment

MGF biology is well-characterized in the muscle physiology literature. The alternative splicing of IGF-1 to produce MGF in response to mechanical loading is documented in human muscle biopsy studies. MGF's role in satellite cell activation has been demonstrated in both in vitro studies (cell culture showing dose-dependent satellite cell proliferation) and in vivo animal models (enhanced muscle regeneration with MGF administration following injury).

The age-related decline in MGF expression is established — older muscle shows reduced MGF splicing in response to exercise, correlating with the age-related decline in muscle repair capacity. This provides a biological rationale for exogenous MGF in older adults.

However, synthetic MGF peptide (the C-terminal peptide used commercially) is not identical to full-length endogenous MGF protein. The commercial peptide corresponds to the unique C-terminal sequence that distinguishes MGF from IGF-1Ea, and this domain has been shown to independently activate satellite cells. But the synthetic peptide's pharmacokinetics (5-7 minute half-life) and the lack of controlled human trials mean that dosing protocols are extrapolated from animal studies and practitioner experience.

PEG-MGF has somewhat more preclinical characterization due to its longer half-life enabling more conventional pharmacological study, but human clinical trials are similarly absent.

The evidence is mechanistically strong, preclinically supported, and clinically unproven.

Monitoring markers

• Perceived recovery: subjective recovery rating (1-10) documented after each training session for injected vs. non-injected muscle groups
• DOMS duration and severity: track hours until soreness resolution for target muscles
• Training volume tolerance: total sets x reps x load per muscle group per week — compare to pre-protocol baseline
• Strength recovery: time (hours) after a training session before the muscle group returns to baseline strength
• Muscle circumference: measure target and control muscle groups at baseline, week 3, and week 6
• CK (creatine kinase): if available, baseline and post-training session levels at week 1 and week 4. Lower post-training CK may indicate reduced muscle damage accumulation
• Sleep quality: rate subjectively, as recovery demands influence sleep patterns
• Injection site assessment: palpate for nodules, swelling, or irritation at intramuscular injection sites

Assessment schedule:

• Baseline: measurements, training log review, recovery baseline
• Week 3: mid-cycle comparison of recovery metrics
• Week 6: end-of-cycle full assessment
• Week 8: post-cycle follow-up to assess sustained benefits

Limitations and considerations

• Extremely short half-life (native MGF): The 5-7 minute half-life means timing and injection site precision are critical. Subcutaneous injection is largely ineffective for native MGF — the peptide degrades before reaching the target muscle systemically. Intramuscular injection is required.
• Injection technique matters: Intramuscular injection into the correct muscle belly requires anatomical knowledge. Injection into fascia, tendon, or subcutaneous tissue misses the target satellite cells entirely.
• No human clinical trial data: All dosing is derived from animal equivalent dosing and in vitro satellite cell studies. Individual response is unpredictable.
• PEG-MGF is a different pharmacological profile: The pegylated version has a fundamentally different mechanism of action — sustained systemic exposure rather than acute local pulse. Users should understand that PEG-MGF and native MGF are not interchangeable protocols despite sharing the same active peptide sequence.
• MGF does not replace rest: Satellite cell activation is the initiating event of repair, but the repair process still requires time, protein synthesis machinery, and energy. Using MGF to train through genuine overtraining will accelerate damage faster than repair can occur.
• Peptide degradation: MGF is one of the least stable peptides in common use. Store reconstituted solution at 2-8 degrees C and use within 2-3 weeks. Degraded peptide is inactive.
• Limited utility as a standalone: MGF addresses one phase of the repair cascade (satellite cell activation). Used alone, it accelerates one bottleneck. Combined with IGF-1 LR3 (which drives the subsequent proliferation phase), the effect is synergistic. As a standalone compound, results are more modest.
• Cost-effectiveness: The requirement for daily intramuscular injections into trained muscles, combined with the peptide's instability and the need for fresh reconstitution, makes MGF one of the more demanding peptide protocols to implement consistently.
• Anti-doping status: MGF and all IGF-1 variants are prohibited by WADA. Competitive athletes must not use this compound.